Clinical Trial

Cardioneuroablation and Ventricular Proarrhythmia

Study acronym: Roman4
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cardioneuroablation (CNA) is a promising tool to treat patients with asystolic reflex syncope. CNA acts through complete or near complete abolition of vagal nerve chronotropic and dromotropic effects on the heart, resulting in sinus node acceleration and improved atrio-ventricular conduction, which in turn prevents vagally-mediated reflex asystole. However, lack of parasympathetic protection may potentially be proarrhythmic, especially on the ventricular level. Whether this is a real threat is not known. Therefore, the aim of our study is to assess acute effects of CNA-induced total vagal denervation, measured by extracardiac vagal stimulation, on ECG and electrophysiological parameters as well as vulnerability to ventricular arrhythmias. The study group will consist of 50 consecutive patients undergoing CNA in our institution. Cardioneuroablation will be performed in standard manner. The following parameters will be assessed at baseline and after CNA (directly after CNA, after atropine injected after CNA and after isoproterenol bolus injected at the very end of the procedure): QTc interval, QT dispersion, right ventricular action potential duration, right ventricular effective refractory period and susceptibility to complex ventricular arrhythmias using programmed ventricular stimulation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-12.
Trial Details
NCT Number NCT06458140
Lead Sponsor Centre of Postgraduate Medical Education
Conditions Syncope, Vasovagal
Enrollment 50 participants
Start Date 2024-05-20
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-14